Characterization of a new set of monoclonal β-amyloid antibodies

β-Amyloid (Aβ) deposition is a commonly studied neuropathology in the human brain, occurring as compact and diffuse parenchymal plaques, cerebral amyloid angiopathy (CAA), and meningeal/subpial amyloidosis. Compact plaques associated with dystrophic neurites generally referred to as neuritic plaques, are a pathological hallmark of Alzheimer's disease (AD). We evaluated three recently developed monoclonal mouse antibodies against Aβ (A1, A2 and A3) using appropriate tissue samples and assay controls in the present study. In immunohistochemistry, antibodies A1, A2 and A3 displayed all forms of cerebral Aβ deposition in a range of dilutions in cryostat and paraffin sections. These labeled profiles appeared morphologically comparable to that visualized by two commercial Aβ antibody clones, 6E10 and D12B2. In immune-dot blotting assays, antibodies A1, A2 and A3 at highly diluted concentrations detected an increase of Aβ in neocortical lysates of AD samples compared to control. Moreover, these antibodies clearly labeled Aβ pathology in brain sections of three commonly used transgenic mouse models of AD, namely, APP/PS1 mice, 5XFAD mice, and 3XTg-AD mice. Taken together, these monoclonal mouse anti-Aβ antibodies can serve as new experimental tools for basic, translational, and diagnostic research into aging and AD-related cerebral Aβ neuropathology in both human and experimental animal brains.